Abstract:
The invention relates to a natamycin dosage form comprising a tablet, which consists of physiologically acceptable components, said tablet containing an effective food preserving amount of natamycin. The invention also relates to a process for producing such a dosage form as well as to a method for preservation of a food product comprising adding natamycin contained in a natamycin dosage form directly or indirectly to a food product to provide a preserving amount of natamycin in said food product.
Abstract:
The present invention provides an antimicrobial composition comprising (i) an antimicrobial material; (ii) an organic acid or salt thereof; and (iii) an emulsifier.
Abstract:
The present invention relates to microcapsules, and more particularly to microcapsules where an aqueous bead or beads comprising the active ingredient is encapsulated in or by a hydrophobic shell matrix. The present invention relates also to novel methods for preparing the microcapsules according to the invention, as well as to the use of the microcapsules of the present invention. A microcapsule of the present invention comprises a solidified hydrophobic shell matrix, an encapsulated aqueous bead or beads which is/are encapsulated in or by the solidified hydrophobic shell matrix, and an active ingredient or active ingredients dissolved or incorporated in the encapsulated aqueous bead or beads.
Abstract:
The present invention provides an antimicrobial material in an encapsulated form, comprising (i) a core comprising an antimicrobial material and (ii) a shell of encapsulating material, wherein the shell of encapsulating material is impermeable to the antimicrobial material. The invention further provides a process for introducing an antimicrobial material into a foodstuff comprising (i) providing the antimicrobial material in an encapsulated form comprising a core of antimicrobial material and shell of encapsulating material, and (ii) introducing encapsulated antimicrobial material into or onto the foodstuff.
Abstract:
A method of storing on a remote storage device protocol information for a drug for administration via a peristaltic pump is disclosed. A communications path between the peristaltic (10) pump and the remote storage device (20) is provided. The protocol information for the drug is entered into the peristaltic pump. The protocol information is transferred from the peristaltic pump to the remote storage device. The protocol information for the drug is stored on the remote storage device. History information may be retrieved from the peristaltic pump. A user request is received requesting retrieval of history information from the peristaltic pump. A pump request is formatted to retrieve history information. The pump request to receive history information is transmitted to the peristaltic pump. The history information is received from the peristaltic pump. The history information can be displayed and/or stored.
Abstract:
A system and method for remote monitoring and/or management of infusion therapies. A user can monitor and manage server-connected pumps at a remote location, such as a computer or PDA. Pumps located at an institution, such as a hospital or patients home, are connected, for example, via the Internet to a server that includes a database of information. A user can operate the pump, from a remote location, by using an interface displayed on the remote site. The operator can manage pump operations by use of the interface. In this context, the user can turn the pump on and off, select infusion rates, dose amounts, etc. all from the convenience of the remote location.
Abstract:
A method of storing on a remote storage device protocol information for a drug for administration via a peristaltic pump is disclosed. A communications path between the peristaltic pump and the remote storage device is provided. The protocol information for the drug is entered into the peristaltic pump. The protocol information is transferred from the peristaltic pump to the remote storage device. The protocol information for the drug is stored on the remote storage device. History information may be retrieved from the peristaltic pump. A user request is received requesting retrieval of history information from the peristaltic pump. A pump request is formatted to retrieve history information. The pump request to receive history information is transmitted to the peristaltic pump. The history information is received from the peristaltic pump. The history information can be displayed and/or stored.
Abstract:
Non-competitive immunoassays and kits for detecting or determining the concentration of an analyte in a biological sample are provided along with reagents for use in such assays and kits. Immunoassays are provided which employ a reagent containing an autologous analyte which raises the signal above the background noise caused by non-specific binding thereby lowering the percent coefficient of variation of a non-competitive assay. By employing an autologous analyte in a reagent of the immunoassay, low dosages of an analyte can be detected without adversely affecting the long linear range of the assay.
Abstract:
The present invention relates to a non yeast-leavened fine bakery product with increased shelf life and to a process for increasing the shelf life of intermediate and high moisture fine bakery products. The fine bakery product comprises an intermediate or high moisture baked product having a water activity a w >0.8. Its surface has deposited thereon an effective amount of natamycin, which is sufficient to keep the product mould free when packaged for a storage time of 2 weeks or more at ambient temperature. In the process the outer surface of a baked product is sprayed with natamycin to deposit an effective amount of natamycin thereon, whereafter the sprayed product is packaged in a protective envelope.
Abstract:
The present invention provides a composition comprising (a) an antimicrobial material; and (b) an extract obtained from or obtainable from a plant of the Labiatae family, wherein (a) and (b) are different; wherein the composition contains phenolic diterpenes in an amount of greater than 1.0wt.%, based on the composition, and wherein when the antimicrobial material consists of nisin, the composition comprises carvacrol in an amount of less than 0.075wt.% based on the composition and carvone in an amount of less than 15wt.% based on the composition.